secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2021-09-08T23:59:59+00:00
Accession:  0001193125-21-267364
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences appoints Dr. Kuchibhatla as SVP Head of R&D; Dr. Saoud to advisory role
--------------------------------------------------------------------------------

- Dr. Jay Saoud resigns as SVP Head of R&D effective Sept 15, 2021; transitions to consultant through June 2022.
- Dr. Ramana Kuchibhatla appointed as Senior VP & Head of R&D effective Sept 16, 2021, reporting to CEO.
- Saoud will continue supporting preparation and submission of NDA for roluperidone (negative symptoms of schizophrenia).
- Consulting fee: $412.50/hr first 20 hrs/wk, $500/hr beyond; equity awards accelerate upon completion or early termination.
- Kuchibhatla has over 35 years drug development experience from PRA Health Sciences, Melior, Targacept, GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312521267364/0001193125-21-267364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312521267364/d196078d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-267364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer